FDAapproval84% confidence
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as Novartis; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Supporting Context
- Therapeutic area
- Oncology · Radiopharmaceutical
- Sub-indication
- Prostate Cancer
Related signal: FDA Approves Lutetium Lu 177 VIPIVOTIDE for Metastatic Prostate Cancer